RxDoctor Payments Data

William Grimm, DO

Internal Medicine · Palm Springs, CANPI 1407841315

Payments from drug & device makers

$709in general payments, 2019–2025

Across 42 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$407
  • Lilly USA, LLC$101
  • AbbVie$97
  • Gilead$40
  • Astellas Pharma US Inc$24
  • EMD Serono, Inc.$19
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$709 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$685,173
Medicare patients
227
Services billed
14,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen88$360,108
DovatoDolutegravir Sodium/Lamivudine60$204,843
KisqaliRibociclib Succinate12$166,028
PrezcobixDarunavir/Cobicistat47$116,691
BiktarvyBictegrav/Emtricit/Tenofov Ala19$84,513
TivicayDolutegravir Sodium35$82,249
DescovyEmtricitabine/Tenofov Alafenam24$60,155
TriumeqAbacavir/Dolutegravir/Lamivudi12$50,095
MounjaroTirzepatide24$43,907
CompleraEmtricita/Rilpivirine/Tenof Df11$37,434
IsentressRaltegravir Potassium14$28,019
EliquisApixaban22$25,577
FaslodexFulvestrant12$22,892
Fosamprenavir Calcium12$22,494
OzempicSemaglutide11$21,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$40$504,776131 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq$407$337,187107 claims
Lilly USA, LLCMounjaro$101$43,90724 claims
MerckIsentress$12$28,01914 claims
PfizerEliquis$11$25,57722 claims
Astellas Pharma US IncMyrbetriq, Veozah$24$20,84340 claims
AbbVieSynthroid$97$1,58616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →